title: Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
abstract: Less frequent bisphosphonate dosing in women with postmenopausal osteoporosis has the potential to promote therapy adherence through improved convenience. Ibandronate is a highly potent nitrogen-containing bisphosphonate, proven to significantly increase vertebral and nonvertebral bone mineral density (BMD) when administered as a convenient intravenous injection. A recent double-blind, placebo-controlled, randomized phase III study explored the antifracture efficacy and safety of 1 and 0.5 mg iv ibandronate injections, given once every 3 months, in 2862 women (55-76 years) with postmenopausal osteoporosis [one to four prevalent vertebral fractures and lumbar spine (L1-L4) BMD T score of less than -2.0 and greater than -5.0 in >or=1 vertebra]. All participants received daily vitamin D (400 IU) and calcium (500 mg) supplementation. The primary endpoint was the incidence of new morphometric vertebral fractures after 3 years. However, although a consistent trend toward a reduction in the incidence of new morphometric vertebral fracture was observed in the active treatment arms compared with placebo (9.2% vs. 8.7% vs. 10.7% in the 1 mg, 0.5 mg and placebo groups, respectively), as well as in the incidence of nonvertebral and hip fractures, the magnitude of fracture reduction was suboptimal and was insufficient to achieve statistical significance. At the studied doses, intravenous ibandronate injections also produced dose-dependent, but comparatively small, increases in lumbar spine BMD (4.0% and 2.9%, respectively) and decreases in biochemical markers of bone resorption and formation, relative to placebo. Optimal fracture efficacy likely requires more substantial increases in BMD and more pronounced suppression of bone turnover. In light of the clear dose-response relationship observed in this and other studies, this is likely to be achieved with higher intravenous doses of ibandronate. The results of a recent phase II/III study (Intermittent Regimen Intravenous Ibandronate Study: the IRIS study) provide support for this hypothesis.
authors.affiliation: Osteoporosis Research Center, Creighton University, Omaha, NE 68178, USA. rrecker@creighton.edu
authors.forename: R
authors.initials: R
authors.lastname: Recker
authors.forename: J A
authors.initials: JA
authors.lastname: Stakkestad
authors.forename: C H
authors.initials: CH
authors.lastname: Chesnut
authors.forename: C
authors.initials: C
authors.lastname: Christiansen
authors.forename: A
authors.initials: A
authors.lastname: Skag
authors.forename: A
authors.initials: A
authors.lastname: Hoiseth
authors.forename: M
authors.initials: M
authors.lastname: Ettinger
authors.forename: P
authors.initials: P
authors.lastname: Mahoney
authors.forename: R C
authors.initials: RC
authors.lastname: Schimmer
authors.forename: P D
authors.initials: PD
authors.lastname: Delmas
mesh_terms: D000368:Aged; D001862:Bone Resorption / Q000188:drug therapy; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D000077557:Ibandronic Acid; D007262:Infusions, Intravenous; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D010919:Placebos; D017698:Postmenopause
chemical_list: D004164:Diphosphonates; D010919:Placebos; D000077557:Ibandronic Acid